Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a ...
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral ...
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...
Vertex Pharmaceuticals’ povetacicept – This BAFF/APRIL dual-pathway inhibitor has emerged as a strong contender in the MN pipeline. Nephrologists view the differentiated mechanism as addressing core ...
WELLESLEY HILLS, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...
A post hoc analysis of the STARMEN trial found that a combination of three early biomarkers can predict 2-year remission in ...
Daniel C. Cattran, MD The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy. The Membranous Nephropathy Trial of Rituximab (MENTOR) study is ...
(Boston) - Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose ...
Rituximab (Rituxan, Genentech) should replace cyclosporine for the treatment of primary membranous nephropathy, say editorialists commenting on the results of the Membranous Nephropathy Trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback